Researchers sought to determine whether MSD HSCT or auto-HSCT would have advantages over chemotherapy in post-remission treatment for patients with AML.

Blood-based proteomic profiling of 251 inflammatory proteins in 543 patients with newly diagnosed acute myeloid leukemia (AML) identifies an eight-protein signature that enhances risk stratification.